The University of Virginia Comprehensive Cancer Center seeks adults ages 18 and over with locally advanced or metastatic solid tumor to participate in a research study. The purpose of the study is to evaluate the investigational drugs MGC018 and MGD019 at different dose levels, and identify which dose of MGC018 in combination with MGD019 is the best dose that subjects can receive while trying to minimize severe symptoms, as well as looking at whether the investigational drugs cause your tumor to shrink or grow more slowly.
The study involves receiving the investigational drugs, as well as coming in for study visits which include exams, laboratory tests, and procedures such as having your blood drawn, talking to the study doctor, and answering questionnaires. Participation includes a screening visit, 1-3 visits per cycle during treatment, an end of treatment visit, and a follow-up period via phone calls to keep track of how you are doing. Treatment cycles for this study are 4 weeks. The time you spend in this study receiving study treatment may last up to 26 cycles or 2 years if you are responding to study treatment and are not having significant side effects.
The investigational drugs, MGC018 and MGD019, as well as study related doctor's visits and laboratory tests, will be provided at no cost to you.
Mileage reimbursement - $58.5 cents per mile
Hotel Reimbursement – up to $175 per night